SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in...

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

the use of spironolactone in patients on dialysis did not alter mortality or hospitalizations for heart failure. Similar results were seen in the simultaneously released ALCHEMY trial.

This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?

This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

Based on data from the CRIC study, this analysis dives deep into whether this lab mismatch is just noise… or a clinical signal we’ve been missing. Check out the beautiful visual abstract made by our NephJC interns Sai Vani Yellampalli and Akshaya Jayachandran . Great team work!!!

This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

Check out the beautiful visual abstract made by NephJC intern Michelle Fravel .

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

The Clinico-Pathological Conference (CPC) is a case-based teaching-learning tool with a rich history, and remains an excellent exercise in clinical deductive reasoning. The origins of the fabled CP…

ALT: a man in a suit says i 'm still a little nervous on a poster for only murders in the building

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.

YouTube video by International Society of Nephrology

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not ...

Is Obinutuzumab Effective and Safe in Active Lupus Nephritis?  Check out the beautiful VA by NSMC Faculty Dr Divya Bajpai on the REGENCY Trial, answering the same.